175 related articles for article (PubMed ID: 20469978)
21. The immunogenicity and reactogenicity of the trivalent vaccine, Trimovax, indicated for prevention of measles, mumps, and rubella, in 12-month-old children in Belarus.
Samoilovich EO; Kapustik LA; Feldman EV; Yermolovich MA; Svirchevskaya AJ; Zakharenko DF; Fletcher MA; Titov LP
Cent Eur J Public Health; 2000 Aug; 8(3):160-3. PubMed ID: 10965439
[TBL] [Abstract][Full Text] [Related]
22. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
Dennehy PH; Saracen CL; Peter G
Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
[TBL] [Abstract][Full Text] [Related]
23. Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.
Yadav S; Thukral R; Chakarvarti A
Indian J Med Res; 2003 Nov; 118():183-6. PubMed ID: 14723482
[TBL] [Abstract][Full Text] [Related]
24. [Epidemiological analysis of immunity against vaccine-preventable diseases: rubella, measles, mumps and chickenpox].
Buxbaum S; Doerr HW; Allwinn R
Dtsch Med Wochenschr; 2001 Nov; 126(46):1289-93. PubMed ID: 11709730
[TBL] [Abstract][Full Text] [Related]
25. Sero-response to measles-mumps-rubella vaccine campaign in Saudi Arabia.
Al-Mazrou YY; Khalil MK; Tumsah S; Al-Ghamdi YS; Al-Jeffri MH; Tischer AB; Mishkhas AA; Eissa M
Saudi Med J; 2002 Jun; 23(6):680-3. PubMed ID: 12070547
[TBL] [Abstract][Full Text] [Related]
26. Immunization status and re-immunization of childhood acute lymphoblastic leukemia survivors.
Toret E; Yel SE; Suman M; Duzenli Kar Y; Ozdemir ZC; Dinleyici M; Bor O
Hum Vaccin Immunother; 2021 Apr; 17(4):1132-1135. PubMed ID: 32882157
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the immune status against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplantation recipients.
Kawamura K; Yamazaki R; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Hematology; 2015 Mar; 20(2):77-82. PubMed ID: 24992512
[TBL] [Abstract][Full Text] [Related]
28. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.
France EK; Glanz J; Xu S; Hambidge S; Yamasaki K; Black SB; Marcy M; Mullooly JP; Jackson LA; Nordin J; Belongia EA; Hohman K; Chen RT; Davis R;
Pediatrics; 2008 Mar; 121(3):e687-92. PubMed ID: 18310189
[TBL] [Abstract][Full Text] [Related]
29. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
30. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
32. Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route.
Díaz-Ortega JL; Bennett JV; Castañeda D; Martinez D; de Castro JF
Vaccine; 2010 Oct; 28(44):7228-32. PubMed ID: 20800111
[TBL] [Abstract][Full Text] [Related]
33. Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy.
Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
Clin Infect Dis; 2010 May; 50(10):1415-8. PubMed ID: 20377409
[TBL] [Abstract][Full Text] [Related]
34. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine.
LeBaron CW; Forghani B; Beck C; Brown C; Bi D; Cossen C; Sullivan BJ
J Infect Dis; 2009 Feb; 199(4):552-60. PubMed ID: 19113988
[TBL] [Abstract][Full Text] [Related]
35. Persistence of antibodies induced by measles-mumps-rubella vaccine in children in India.
Raut SK; Kulkarni PS; Phadke MA; Jadhav SS; Kapre SV; Dhere RM; Dhorje SP; Godse SR
Clin Vaccine Immunol; 2007 Oct; 14(10):1370-1. PubMed ID: 17699834
[TBL] [Abstract][Full Text] [Related]
36. Differential loss of humoral immunity against measles, mumps, rubella and varicella-zoster virus in children treated for cancer.
Bochennek K; Allwinn R; Langer R; Becker M; Keppler OT; Klingebiel T; Lehrnbecher T
Vaccine; 2014 Jun; 32(27):3357-61. PubMed ID: 24793952
[TBL] [Abstract][Full Text] [Related]
37. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ;
Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343
[TBL] [Abstract][Full Text] [Related]
38. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
Clin Infect Dis; 2007 Sep; 45(5):637-42. PubMed ID: 17683001
[TBL] [Abstract][Full Text] [Related]
39. Revaccination of children after completion of standard chemotherapy for acute leukemia.
Patel SR; Ortín M; Cohen BJ; Borrow R; Irving D; Sheldon J; Heath PT
Clin Infect Dis; 2007 Mar; 44(5):635-42. PubMed ID: 17278052
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
